Redmond, WA – According to filings with the U.S. Securities and Exchange Commission, Eliem Therapeutics is raising $59,999,987.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Bob Azelby played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Eliem Therapeutics

Eliem Therapeutics is a biotechnology company delivering therapies that empower patients to live on their own terms. Backed by RA Capital Management, Access Biotechnology, and Intermediate Capital Group, Eliem channels its experience, energy, and passion for improving patients’ quality of life by developing and commercializing potentially best-in-class drug candidates to treat neuronal excitability disorders. These conditions such as chronic pain, depression, epilepsy, and anxiety cause deep suffering for tens of millions of people each day. At its core, the Eliem team is motivated by the promise of helping patients live happier, more fulfilling lives. Eliem is founded and led by a team of seasoned industry executives who collectively bring decades of clinical development and biopharmaceutical commercialization experience to the company. The team not only shares an unparalleled determination and passion to help patients, but they also have a history of working together to successfully build companies and bring novel and effective therapies to market.

To learn more about Eliem Therapeutics, visit http://www.eliemtx.com/

Contact:
Bob Azelby, President and Chief Executive Officer
425-276-2300
https://www.linkedin.com/in/bob-azelby-628ab51/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved